🎯 check Tanespimycin (17-AAG) product page
Tanespimycin (17-AAG) is a potent N-terminal HSP90 inhibitor. It affects AKT/GSK3β, JAK/STAT, and MAPK signaling pathways by inhibiting HSP90 chaperone function and degrading client proteins, effectively inhibiting cell proliferation, migration, and viral replication, and promoting apoptosis.